ICM was founded in 1997 and established as the first private genetic laboratory in Spain. It was created in the spirit of serving the medical community through the characterisation and molecular diagnosis of genetic conditions.
2020 is integrated into Atrys Health, a Spanish multinational founded in 2015 that provides precision medical diagnosis and treatment services and is a pioneer in the fields of telemedicine and next-generation radiotherapy.
Over the past 20 years, ICM has consolidated itself as a genetics reference centre, offering its services to a significant number of laboratories in Spain, public and private hospitals, universities and medical insurers.
Throughout this time, ICM has gradually been adopting the latest technologies in order to offer its customers the best diagnostic portfolio. ICM currently boasts a catalogue of more than 3,000 genetic tests, at very competitive prices and response times, all in adherence to the most stringent quality standards.
The development of next-generation sequencing technologies in recent years has meant that millions of DNA sequences can now be obtained at unprecedented speeds and at vastly reduced costs. These technologies allow new genes as well as new mutations that are responsible for genetic diseases to be identified, which has led the current revolution in postnatal and prenatal diagnostics.
ICM has remained at the forefront of all these advances and, with the intention of offering the best services of the highest quality to all their customers, has heavily invested in the most advanced technology on the market.
Next-generation sequencing (NGS) is one of these technologies, which ICM implements with the most advanced technological platforms.
In addition, high-capacity SNP platforms are provided for use in the field of preventive medicine and personalised genetics. This technology facilitates the detection of thousands of genetic variants that are analysed by our team of bioinformatics experts using state-of-the-art resources. Offering the best response times, highly confidential reports are then drawn up and issued to customers.
Throughout its 20 years of experience, ICM has been evaluating the most advanced technology to emerge at all stages, adopting all those that allow for the establishment and implementation of the best diagnostic solutions. As a result, ICM is able to produce almost any type of genetic test as it has invested in all the necessary technology for this purpose.
ICM provides specialists with comprehensive solutions specifically designed to cover all individual diagnostic needs.
The great diversity of ICM technology allows technical solutions adapted to each individual need to be adopted, in all cases supported by an expert team of advisors and geneticists.
ICM has signed a strategic agreement with the bioinformatics company Helix BioS to develop Spain’s largest genomic data analysis platform with the capacity to process more than 15 Tb per week. Combining a system of data compression specifically designed for that purpose with a dedicated fibre network and powerful data analysis engines, ICM aims to transform the diagnostic panorama with the first clinical diagnostic unit based on whole-genome sequencing and long-read sequencing, thereby offering the greatest coverage and diagnostic precision at costs similar to classic NGS systems available up to now.
Sobre Helix BioS:
Helix BioS is an international bioinformatics company with its headquarters in Madrid. It provides analytical services for biological data and advice to industries and research groups in various sectors, including health, agriculture, mining and many more. Their international team has vast experience with biotechnology, genetics, biomedicine, computational technology, big data and artificial intelligence.
To consolidate our position as the leading genetics centre, with a team of expert geneticists and with the most advanced technology in order to provide the medical community and its patients with a wider catalogue of genetic diagnostic and preventive tests.
To make genetics an accessible tool for everyone and for all medical specialties, for personalised diagnosis and treatment, and for the prevention of genetic diseases.
Passionate. Committed. Knowledgeable. Professional. Competitive. Dedicated.
A large company can only thrive thanks to its great foundation of workers. ICM is built on a team of professionals who have demonstrated their great worth throughout all these years as they have grown. Get to know us.
Executive President of Atrys
CEO of Atrys
CFO of Atrys
Chief Technical Officer of Genetics
Having been the Technical and Scientific Director at ICM since its creation, Severino is directly responsible for ICM’s positioning as a world leader in technological innovation and diagnostics. All technological advances in the field of genetics and molecular biology are immediately analysed and evaluated in the context of clinical diagnostics for exclusion or inclusion at ICM.
Severino has developed technology and diagnostic solutions for products currently being marketed by large multinationals, which has given him a wealth of experience in spotting the best technological opportunities and diagnostic applications. Severino trained as a specialist at Hospital Universitario Central in Asturias, placing first in the national qualification for the BIR (Biologist/Biochemist resident) immunology programme. He has made numerous scientific contributions with the publication of several cited articles and won the Outstanding Doctoral Thesis Award. Since becoming Founding Partner and Technical Director of ICM in 1997, to date, he has developed and verified more than 3,000 genetic tests for ICM’s portfolio.
Over the course of Severino’s career at ICM spanning more than 2 decades, our Centre has been recognised on numerous occasions for its specialisation and technical capacity thanks to the outstanding efforts of its Technical and Scientific Director. Severino became a contracted investigator at Universidad de A Coruña, responsible for developing the teaching programme that ICM developed with Universidad de Santiago de Compostela.
Vice President of Genetics
He began his specialised training at the Tumour Biology Unit of Hospital Universitario Central de Asturias, also completing placements at the Hospital Universitario La Fe in Valencia as well as the Cancer Research UK Imperial Centre in London. He has shown great passion and dedication to his work since the beginning of the project, allowing ICM to grow and develop into a great company. His research work has been based on his passion for genetics. More than 100 of his articles have been published in indexed scientific journals, as well as 21 book chapters, and he has received numerous accolades thanks to his great corporate accomplishments and extensive knowledge in genetics.
Continuing on from his Doctoral Thesis project, Alfonso has made great strides in the field of cervical cancer, having been influential in the implementation of vaccination programmes against HPV and assuming the role of Scientific Advisor and Member of the Executive Board of the principal associations involved in this field, both in Spain and internationally. Institutionally, since 2002 Alfonso has been a permanent member on a panel of expert advisors of the Spanish Ministry of Science and Technology and of the National Plan of R&D in Technology, as well as a member of the Committee of Experts for the Health Commission of the European Union.
He is highly skilled in conveying his knowledge, having been invited as a speaker on more than 400 occasions, both within Spain and internationally, as well as being asked to speak more than 10 times in his capacity as professor at world congresses. Alfonso also worked as a professor at the Universidad Autónoma de Barcelona, Universidad de Vigo and Universidad de A Coruña. Considering his vast experience in the area of genetics, he has been appointed as an advisor in this area for the hospital group Quirónsalud. Today, he is still working with the same commitment and enthusiasm that he showed on his first day.
Follow all news
Política de Calidad
COPYRIGHT © 2017-2023 ICM. ALL RIGHTS RESERVED